 DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a public offering of its ordinary shares or pre-funded warrants in lieu thereof. All of the ordinary shares or pre-funded warrants in lieu thereof in the offering will be sold by Nabriva Therapeutics. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 